NewGen Therapeutics, Inc. today announced that it will present an abstract entitled “NT113, A Potent and Selective Pan-erbB inhibitor, is Efficacious in Vivo and Has High Brain Penetrance” at the American Association of Cancer Research Meeting (AACR), being held April 6-10, 2013 in Washington, D.C.
